Stock NRSN NEUROSENSE THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus NeuroSense Therapeutics Ltd.

Equities

NRSN

IL0011809592

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.23 USD -2.38% Intraday chart for NeuroSense Therapeutics Ltd. -13.38% +56.69%
Apr. 22 NeuroSense to Collaborate With Genetika+ on Alzheimer's Disease Drug Development; Shares Fall MT
Apr. 22 NeuroSense Therapeutics Ltd. and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease CI

Evolution of the average Target Price on NeuroSense Therapeutics Ltd.

Price target over the last 5 years

History of analyst recommendation changes

c4c7d56b4729b8bce0ab15a.FgMtEs_N5GaJPsiqA-luLLimqzDkrtZ6tppxXjPT6_I.Y1EVaIj6oRS8T4TQaIAeYo_L33fd_KAv7Ms5blC_gIEvRABmuLWvS8FOjQ~f8805286d4673cf67950ee9d18215a04

Analyst Recommendations on NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Prices $4.5 Million Offering of Ordinary Shares, Warrants MT
Alliance Global Partners Initiates NeuroSense Therapeutics at Buy Rating With $7.50 Price Target MT
Maxim Starts NeuroSense Therapeutics at Buy with $7 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.23 USD
Average target price
5.25 USD
Spread / Average Target
+326.83%
High Price Target
7.5 USD
Spread / Highest target
+509.76%
Low Price Target
3 USD
Spread / Lowest Target
+143.90%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NeuroSense Therapeutics Ltd.

Alliance Global Partners
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NRSN Stock
  4. Consensus NeuroSense Therapeutics Ltd.